Natural killer cell therapy for high-risk lymphoma with Sjogren's syndrome
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of immune cell therapy using natural killer cells to treat people who have both high-risk lymphoma and primary Sjogren's syndrome. The goal is to see if these cells can safely and effectively fight the lymphoma while managing the autoimmune condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have primary Sjogren's syndrome diagnosed by standard criteria.
- You must have ongoing enlargement of salivary glands, lymph nodes, liver, or spleen, plus at least two of the following: cryoglobulinemia, low C4, low white blood cells, or positive anti-SSA/SSB antibodies.
- Your liver and kidney function must be within safe limits (specific lab values apply).
- You cannot be pregnant or breastfeeding, and must not have active hepatitis B, C, or HIV.
- You cannot have a history of severe allergies, other autoimmune diseases, or major organ failure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new type of immune cell therapy (CD19 CAR NK cells) for people with certain autoimmune diseases that have not responded to standard treatments. The goal is to see if these cells can safely reduce disease activity.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.